Literaturverzeichnis

1. Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother. 53:844-854.

2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 19:3622-3634.

3. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, Jewell WR, Bartolucci AA, Mihm MC, Jr., Barnhill R, . (1993) Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 218:262-267.

4. Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK, Fay J (2005) Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother. 28:505-516.

5. Barth A, Wanek LA, Morton DL (1995) Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll.Surg. 181:193-201.

6. Boon T, Old LJ (1997) Cancer Tumor antigens. Curr.Opin Immunol. 9:681-683.

7. Borsi L, Carnemolla B, Castellani P, Rosellini C, Vecchio D, Allemanni G, Chang SE, Taylor-Papadimitriou J, Pande H, Zardi L (1987) Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol. 104:595-600.

8. Buzaid AC (2004) Management of metastatic cutaneous melanoma. Oncology (Williston.Park). 18:1443-1450.

9. Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG (1989) A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol. 108:1139-1148.

10. Coory M, Baade P, Aitken J, Smithers M, McLeod GR, Ring I (2006) Trends for in situ and Invasive Melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control. 17:21-27.

11. de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN (1997) Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 57:3223-3229.

12. Dorval T, Negrier S, Chevreau C, Avril MF, Baume D, Cupissol D, Oskam R, de Peuter R, Vinke J, Herrera A, Escudier B (1999) Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer. 85:1060-1066.

13. Ebbinghaus C, Scheuermann J, Neri D, Elia G (2004) Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr.Pharm.Des. 10:1537-1549.

14. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, Glass E, Morton DL (1999) Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg.Oncol. 6:442-449.

15. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH (1998) Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 16:1743-1751.

16. Garbe C, Blum A (2001) Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol.Appl.Skin Physiol. 14:280-290.

17. Garbe C, Ellwanger U, Tronnier M, Brocker EB, Orfanos CE (2002) The New American Joint Committee on Cancer staging system for cutaneous melanoma: a critical analysis based on data of the German Central Malignant Melanoma Registry. Cancer. 94:2305-2307.

18. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO (2004) Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol. 165:1853-1863.

19. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI (1999) Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 17:976-983.

20. Goldberg SM, Bartido SM, Gardner JP, Guevara-Patino JA, Montgomery SC, Perales MA, Maughan MF, Dempsey J, Donovan GP, Olson WC, Houghton AN, Wolchok JD (2005) Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res. 11:8114-8121.

21. Hersey P (2006) Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Curr.Opin Oncol. 18:189-196.

22. Hicklin DJ, Marincola FM, Ferrone S (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today. 5:178-186.

23. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S (1998) beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 101:2720-2729.

24. Houghton AN (1984) Identification of differentiation antigens of melanoma and melanocytes by mouse and human monoclonal antibodies. Transplant.Proc. 16:351-354.

25. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin. 54:8-29.

26. Kawakami Y, Rosenberg SA (1996) T-cell recognition of self peptides as tumor rejection antigens. Immunol Res. 15:179-190.

27. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA (1992) Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol. 148:638-643.

28. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 3:999-1005.

29. Knuth A, Wolfel T, Klehmann E, Boon T, Meyer zum Buschenfelde KH (1989) Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc.Natl.Acad Sci.U.S.A. 86:2804-2808.

30. Komenaka I, Hoerig H, Kaufman HL (2004) Immunotherapy for melanoma. Clin Dermatol. 22:251-265.

31. Letsch A, Keilholz U, Fluck M, Nagorsen D, Asemissen AM, Schmittel A, Thiel E, Scheibenbogen C (2005) Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients. Int J Cancer. 114:936-941.

32. Lozupone F, Rivoltini L, Luciani F, Venditti M, Lugini L, Cova A, Squarcina P, Parmiani G, Belardelli F, Fais S (2003) Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol. 33:556-566.

33. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT (1996) Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest. 98:1633-1641.

34. Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM (2005) One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and

stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 174:1751-1759.

35. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 74:181-273.:181-273.

36. Menrad A, Menssen HD (2005) ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets. 9:491-500.

37. Ordonez NG, Ji XL, Hickey RC (1988) Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol. 90:385-390.

38. Pierschbacher MD, Ruoslahti E (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature. 309:30-33.

39. Piro LD (2004) Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology (Williston.Park). 18:5-10.

40. Qian F, Zhang ZC, Wu XF, Li YP, Xu Q (2005) Interaction between integrin alpha(5) and fibronectin is required for metastasis of B16F10 melanoma cells. Biochem.Biophys.Res Commun. 333:1269-1275.

41. Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 50:3-15.

42. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC (1998) HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol. 161:6970-6976.

43. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G (2002) Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev. 188:97-113.:97-113.

44. Romero P, Pannetier C, Herman J, Jongeneel CV, Cerottini JC, Coulie PG (1995) Multiple specificities in the repertoire of a melanoma patient's cytolytic T

lymphocytes directed against tumor antigen MAGE-1.A1. J Exp Med. 182:1019-1028.

45. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med. 10:909-915.

46. Ruoslahti E (1994) Cell adhesion and tumor metastasis. Princess Takamatsu Symp. 24:99-105.:99-105.

47. Ruoslahti E (1999) Fibronectin and its integrin receptors in cancer. Adv Cancer Res. 76:1-20.:1-20.

48. Schwartz RH (1990) A cell culture model for T lymphocyte clonal anergy. Science. 248:1349-1356.

49. Sharpless SM, Das Gupta TK (1998) Surgery for metastatic melanoma. Semin Surg.Oncol. 14:311-318.

50. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene. %19;22:3138-3151.

51. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM (1998) Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg.Oncol. 67:228-233.

52. Thomson TM, Real FX, Murakami S, Cordon-Cardo C, Old LJ, Houghton AN (1988) Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol. 90:459-466.

53. Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM (2005) Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother. 28:382-388.

54. Ugurel S, Uhlig D, Pfohler C, Tilgen W, Schadendorf D, Reinhold U (2004) Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother. 53:551-559.

55. Urosevic M, Dummer R (2003) HLA-G in skin cancer: a wolf in sheep's clothing? Hum.Immunol. 64:1073-1080.

56. Uyttenhove C, Godfraind C, Lethe B, Amar-Costesec A, Renauld JC, Gajewski TF, Duffour MT, Warnier G, Boon T, Van den Eynde BJ (1997) The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer. 70:349-356.

57. Valmori D, Dutoit V, Ayyoub M, Rimoldi D, Guillaume P, Lienard D, Lejeune F, Cerottini JC, Romero P, Speiser DE (2003) Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 3:15.:15.

58. van der BP, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den EB, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643-1647.

59. Walker EB, Haley D, Miller W, Floyd K, Wisner KP, Sanjuan N, Maecker H, Romero P, Hu HM, Alvord WG, Smith JW, Fox BA, Urba WJ (2004) gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res. 10:668-680.

60. Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P (2006) Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by Cisplatin. Clin Cancer Res. 12:1355-1364.